We are live on ! Find out more
RLAY icon

Relay Therapeutics

115 hedge funds and large institutions have $3.64B invested in Relay Therapeutics in 2020 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 32 increasing their positions, 20 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

182% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 11

60% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 20

22% more funds holding

Funds holding: 94 → 115 (+21)

0% more funds holding in top 10

Funds holding in top 10: 11 → 11 (0)

2.91% less ownership

Funds ownership: 100.36% → 97.46% (-2.9%)

41% less capital inflows, than outflows

Capital inflows: $191M | Capital outflows: $325M

Holders
115
Holders Change
+21
Holders Change %
+22.34%
% of All Funds
2.03%
Holding in Top 10
11
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.19%
New
31
Increased
32
Reduced
20
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

RLAY Hedge Fund Activity: Q4 2020 in Review

115 of the 5,678 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q4 2020, worth a combined $3.64B — up 0.02% from $3.64B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new RLAY positions and 11 closed out — a net gain of 20 holders — while 32 added to existing stakes and 20 trimmed.

The largest buyer was BlackRock, adding an estimated $49.3M. The largest seller was Baillie Gifford & Co, cutting an estimated $252M.

  • 115 institutional investors held Relay Therapeutics (RLAY) as of Q4 2020, up from 94 in Q3 2020.
  • Funds reported $3.64B of Relay Therapeutics stock for Q4 2020, up 0.02% quarter-over-quarter.
  • 31 funds opened new Relay Therapeutics positions in Q4 2020 and 11 closed out, a net change of +20 holders.
  • The largest Relay Therapeutics buyer in Q4 2020 was BlackRock, an estimated $49.3M added.
  • The largest Relay Therapeutics seller in Q4 2020 was Baillie Gifford & Co, an estimated $252M sold.

Based on aggregated 13F filings for Q4 2020.